{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:33:57Z","timestamp":1790048037084,"version":"4.0.1"},"reference-count":116,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.ejca.2020.10.014","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T18:32:23Z","timestamp":1605810743000},"page":"63-82","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Efficacy of cancer vaccines in selected gynaecological breast and ovarian\u00a0cancers: A 20-year systematic review and meta-analysis"],"prefix":"10.1016","volume":"142","author":[{"given":"U.","family":"Dafni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mart\u00edn-Lluesma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Balint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Tsourti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Vervita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Chenal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Coukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Zaman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Sarivalasis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.E.","family":"Kandalaft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2020.10.014_bib1","first-page":"1","article-title":"Anti-infectious human vaccination in historical perspective","author":"D'Amelio","year":"2015","journal-title":"Int Rev Immunol"},{"key":"10.1016\/j.ejca.2020.10.014_bib2","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1002\/emmm.201403876","article-title":"Vaccines for the 21st century","volume":"6","author":"Delany","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.ejca.2020.10.014_bib3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nm1100","article-title":"Cancer immunotherapy: moving beyond current vaccines","volume":"10","author":"Rosenberg","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2020.10.014_bib4","first-page":"72","article-title":"Personalized approaches to active immunotherapy in cancer","volume":"1865","author":"Ophir","year":"2016","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ejca.2020.10.014_bib5","doi-asserted-by":"crossref","first-page":"16013","DOI":"10.1073\/pnas.0500090102","article-title":"The response of autologous T cells to a human melanoma is dominated by mutated neoantigens","volume":"102","author":"Lennerz","year":"2005","journal-title":"P Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2020.10.014_bib6","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.it.2018.04.005","article-title":"Update on tumour neoantigens and their utility: why it is good to Be different","volume":"39","author":"Lee","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ejca.2020.10.014_bib7","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1034\/j.1600-065X.2001.1820104.x","article-title":"Control of T-cell activation by CD4+ CD25+ suppressor T cells","volume":"182","author":"Shevach","year":"2001","journal-title":"Immunol Rev"},{"key":"10.1016\/j.ejca.2020.10.014_bib8","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0065-2776(03)81008-8","article-title":"Control of autoimmunity by naturally arising regulatory CD4+ T cells","volume":"81","author":"Hori","year":"2003","journal-title":"Adv Immunol"},{"key":"10.1016\/j.ejca.2020.10.014_bib9","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression - implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib10","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s00262-006-0225-8","article-title":"Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients","volume":"56","author":"Ghiringhelli","year":"2007","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2020.10.014_bib11","doi-asserted-by":"crossref","first-page":"2862","DOI":"10.1182\/blood-2004-06-2410","article-title":"Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide","volume":"105","author":"Lutsiak","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2020.10.014_bib12","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s00262-011-1081-8","article-title":"Phase I\/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission","volume":"61","author":"Chu","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ejca.2020.10.014_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib14","doi-asserted-by":"crossref","first-page":"E670","DOI":"10.1002\/ijc.27388","article-title":"Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: a single-arm phase II study","volume":"131","author":"Vermeij","year":"2012","journal-title":"Int J Canc"},{"key":"10.1016\/j.ejca.2020.10.014_bib15","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1007\/s00262-004-0520-1","article-title":"Dendritic cells can be rapidly expanded ex vivo and safely administered in patients with metastatic breast cancer","volume":"53","author":"Dees","year":"2004","journal-title":"Canc Immunol Immunother"},{"key":"10.1016\/j.ejca.2020.10.014_bib16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.2174\/156800961506150805145120","article-title":"Immune checkpoint inhibitors for cancer therapy: clinical efficacy and safety","volume":"15","author":"Azoury","year":"2015","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ejca.2020.10.014_bib17","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1073\/pnas.0712237105","article-title":"Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients","volume":"105","author":"Hodi","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ejca.2020.10.014_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1080\/21645515.2016.1259043","article-title":"Vaccine delivery systems","volume":"13","author":"Donnelly","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.ejca.2020.10.014_bib19","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/biomedicines4020010","article-title":"Cancer vaccines in ovarian cancer: how can we improve?","volume":"4","author":"Martin Lluesma","year":"2016","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejca.2020.10.014_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2020.10.014_bib21","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.molonc.2010.11.003","article-title":"Deconstructing the molecular portraits of breast cancer","volume":"5","author":"Prat","year":"2011","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib22","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1200\/JCO.2011.41.0902","article-title":"Prognostic and predictive value of tumour-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98","volume":"31","author":"Loi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s10549-014-3185-2","article-title":"The prognostic value of tumour-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis","volume":"148","author":"Ibrahim","year":"2014","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejca.2020.10.014_bib24","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/annonc\/mdu191","article-title":"Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients","volume":"25","author":"Ali","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib25","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2020.10.014_bib26","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ygyno.2011.09.039","article-title":"Prognostic significance of tumour-infiltrating T cells in ovarian cancer: a meta-analysis","volume":"124","author":"Hwang","year":"2012","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib27","doi-asserted-by":"crossref","first-page":"viii1","DOI":"10.1093\/annonc\/mdx444","article-title":"Immunotherapy in ovarian cancer","volume":"28","author":"Odunsi","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib28","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.19.00508","article-title":"Immunotherapy in ovarian cancer: are we there yet?","author":"Kandalaft","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejca.2020.10.014_bib30","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1093\/annonc\/mdz398","article-title":"Efficacy of adoptive therapy with tumour-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis","volume":"30","author":"Dafni","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib31","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2020.10.014_bib32","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2020.10.014_bib33","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2020.10.014_bib34","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Contr Clin Trials"},{"key":"10.1016\/j.ejca.2020.10.014_bib35","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.cct.2015.09.002","article-title":"Meta-analysis in clinical trials revisited","volume":"45","author":"DerSimonian","year":"2015","journal-title":"Contemp Clin Trials"},{"key":"10.1016\/j.ejca.2020.10.014_bib36","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.ejca.2020.10.014_bib37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2020.10.014_bib38","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejca.2020.10.014_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2019.00467","article-title":"Therapeutic cancer vaccine and combinations with antiangiogenic therapies and immune checkpoint blockade","volume":"10","author":"Mougel","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ejca.2020.10.014_bib40","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-016-1027-1","article-title":"Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment","volume":"14","author":"Papa","year":"2016","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2020.10.014_bib41","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"18","author":"Pujade-Lauraine","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2020.10.014_bib42","series-title":"ASCO virtual scientific program","article-title":"Overall survival (OS) results from SOLO2\/ENGOT-ov21: a phase III trial assessing maintenance olaparib in patients (pts) with platinum-sensitive, relapsed ovarian cancer and a BRCA mutation","author":"Final","year":"2020"},{"key":"10.1016\/j.ejca.2020.10.014_bib43","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ctrv.2018.12.002","article-title":"PARP inhibitors in ovarian cancer","volume":"73","author":"Franzese","year":"2019","journal-title":"Canc Treat Rev"},{"key":"10.1016\/j.ejca.2020.10.014_bib44","doi-asserted-by":"crossref","first-page":"eaaz8235","DOI":"10.1126\/scitranslmed.aaz8235","article-title":"Strong vaccine responses during chemotherapy are associated with prolonged cancer survival","volume":"12","author":"Melief","year":"2020","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2020.10.014_bib45","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumour-specific vaccine for patients with incurable human papillomavirus 16\u2013related cancer: a phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncology"},{"key":"10.1016\/j.ejca.2020.10.014_bib46","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41573-020-0074-8","article-title":"Antitumour dendritic cell vaccination in a priming and boosting approach","volume":"19","author":"Harari","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.ejca.2020.10.014_bib47","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.copbio.2020.03.003","article-title":"Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?","volume":"65","author":"Martin-Lluesma","year":"2020","journal-title":"Curr Opin Biotechnol"},{"issue":"2","key":"10.1016\/j.ejca.2020.10.014_bib48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/vaccines4020019","article-title":"Entirely carbohydrate-based vaccines: an emerging field for specific and selective immune responses","volume":"4","author":"Nishat","year":"2016","journal-title":"Vaccines"},{"issue":"5","key":"10.1016\/j.ejca.2020.10.014_bib49","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/PPO.0b013e3182325e63","article-title":"Viral vector-based therapeutic cancer vaccines","volume":"17","author":"Larocca","year":"2011","journal-title":"Cancer J"},{"issue":"9","key":"10.1016\/j.ejca.2020.10.014_bib50","doi-asserted-by":"crossref","first-page":"5789","DOI":"10.1128\/IAI.73.9.5789-5798.2005","article-title":"Pathogenicity and immunogenicity of a vaccine strain of listeria monocytogenes that relies on a suicide plasmid to supply an essential gene product","volume":"73","author":"Zhao","year":"2005","journal-title":"Infect Immun"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib51","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4049\/jimmunol.173.1.420","article-title":"Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy","volume":"173","author":"Starks","year":"2004","journal-title":"J Immunol"},{"issue":"5","key":"10.1016\/j.ejca.2020.10.014_bib52","first-page":"495","article-title":"Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients","volume":"15","author":"Jiang","year":"2000","journal-title":"Cancer Biother Radiopharm"},{"issue":"5","key":"10.1016\/j.ejca.2020.10.014_bib53","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/00002371-200009000-00007","article-title":"Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer","volume":"23","author":"Scholl","year":"2000","journal-title":"J Immunother"},{"issue":"12","key":"10.1016\/j.ejca.2020.10.014_bib54","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1097-0142(20001215)89:12<2646::AID-CNCR18>3.0.CO;2-A","article-title":"Intratumoral injection of dendritic cells derived in vitro in patients with metastatic cancer","volume":"89","author":"Triozzi","year":"2000","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ejca.2020.10.014_bib55","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1073\/pnas.051626298","article-title":"Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: a phase I trial","volume":"98","author":"Gilewski","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"10.1016\/j.ejca.2020.10.014_bib56","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00262-002-0317-z","article-title":"Mucin gene (MUC1) transfected dendritic cells as vaccine: results of a phase I\/II clinical trial","volume":"51","author":"Pecher","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"11","key":"10.1016\/j.ejca.2020.10.014_bib57","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1089\/104303403322124828","article-title":"Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results","volume":"14","author":"Dols","year":"2003","journal-title":"Hum Gene Ther"},{"issue":"4","key":"10.1016\/j.ejca.2020.10.014_bib58","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.3816\/CBC.2003.s.004","article-title":"The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope)","volume":"3","author":"Holmberg","year":"2003","journal-title":"Clin Breast Cancer"},{"issue":"14","key":"10.1016\/j.ejca.2020.10.014_bib59","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1158\/1078-0432.CCR-04-0347","article-title":"Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses","volume":"10","author":"Avigan","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2020.10.014_bib60","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s00262-003-0493-5","article-title":"Vaccination with p53-peptide-pulsed dendritic cells, of patients with advanced breast cancer: report from a phase I study","volume":"53","author":"Svane","year":"2004","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib61","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1158\/1078-0432.CCR-0620-3","article-title":"Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes","volume":"10","author":"Vonderheide","year":"2004","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ejca.2020.10.014_bib62","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s10549-006-9235-7","article-title":"Advanced breast cancer: anti-progressive immunotherapy using a thermostable autologous hemoderivative","volume":"100","author":"Lasalvia-Prisco","year":"2006","journal-title":"Breast Cancer Res Treat"},{"issue":"3 Pt 1","key":"10.1016\/j.ejca.2020.10.014_bib63","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1158\/1078-0432.CCR-05-1574","article-title":"Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma","volume":"12","author":"Loveland","year":"2006","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.ejca.2020.10.014_bib64","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/jjco\/hyl005","article-title":"A phase I\/II trial of a WT1 (Wilms\u2019 tumor gene) peptide vaccine in patients with solid malignancy: safety assessment based on the phase I data","volume":"36","author":"Morita","year":"2006","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib65","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1379\/CSC-218R.1","article-title":"A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients","volume":"12","author":"Ciocca","year":"2007","journal-title":"Cell Stress Chaperones"},{"issue":"10","key":"10.1016\/j.ejca.2020.10.014_bib66","doi-asserted-by":"crossref","first-page":"2977","DOI":"10.1158\/1078-0432.CCR-06-2189","article-title":"Immunization of high-risk breast cancer patients with clustered sTn-KLH conjugate plus the immunologic adjuvant QS-21","volume":"13","author":"Gilewski","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib67","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1177\/030089160709300106","article-title":"Results of a pilot trial of immunotherapy with dendritic cells pulsed with autologous tumor lysates in patients with advanced cancer","volume":"93","author":"Mayordomo","year":"2007","journal-title":"Tumori"},{"key":"10.1016\/j.ejca.2020.10.014_bib68","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/1479-5876-5-42","article-title":"Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2","volume":"5","author":"Morse","year":"2007","journal-title":"J Transl Med"},{"issue":"24","key":"10.1016\/j.ejca.2020.10.014_bib69","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2006.10.5718","article-title":"Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer","volume":"25","author":"Park","year":"2007","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2020.10.014_bib70","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1007\/s00262-007-0293-4","article-title":"Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers","volume":"56","author":"Svane","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"10.1016\/j.ejca.2020.10.014_bib71","doi-asserted-by":"crossref","first-page":"3060","DOI":"10.1158\/1078-0432.CCR-08-0126","article-title":"Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma","volume":"14","author":"Gulley","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2020.10.014_bib72","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1479-5876-6-24","article-title":"Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer","volume":"6","author":"Tsuruma","year":"2008","journal-title":"J Transl Med"},{"issue":"28","key":"10.1016\/j.ejca.2020.10.014_bib73","doi-asserted-by":"crossref","first-page":"4685","DOI":"10.1200\/JCO.2008.20.6789","article-title":"Concurrent trastuzumab and HER2\/neu-specific vaccination in patients with metastatic breast cancer","volume":"27","author":"Disis","year":"2009","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ejca.2020.10.014_bib74","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1200\/JCO.2009.22.3883","article-title":"Phase I active immunotherapy with combination of two chimeric, human epidermal growth factor receptor 2, B-cell epitopes fused to a promiscuous T-cell epitope in patients with metastatic and\/or recurrent solid tumors","volume":"27","author":"Kaumaya","year":"2009","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ejca.2020.10.014_bib75","doi-asserted-by":"crossref","first-page":"5937","DOI":"10.1158\/1078-0432.CCR-08-3282","article-title":"A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2\/neu","volume":"15","author":"Peethambaram","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2020.10.014_bib76","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/1479-5876-8-53","article-title":"Vaccination with a plasmid DNA encoding HER-2\/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial","volume":"8","author":"Norell","year":"2010","journal-title":"J Transl Med"},{"key":"10.1016\/j.ejca.2020.10.014_bib77","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1186\/1479-5876-9-178","article-title":"Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I\/II trial","volume":"9","author":"Baek","year":"2011","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.ejca.2020.10.014_bib78","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1634\/theoncologist.2010-0307","article-title":"Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer","volume":"16","author":"Miles","year":"2011","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ejca.2020.10.014_bib79","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1158\/1078-0432.CCR-10-2614","article-title":"MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer","volume":"17","author":"Morse","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2020.10.014_bib80","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1479-5876-10-28","article-title":"Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition [corrected]","volume":"10","author":"Hamilton","year":"2012","journal-title":"J Transl Med"},{"issue":"9","key":"10.1016\/j.ejca.2020.10.014_bib81","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1007\/s00262-011-1192-2","article-title":"Autologous dendritic cell vaccine for estrogen receptor (ER)\/progestin receptor (PR) double-negative breast cancer","volume":"61","author":"Qi","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"134","key":"10.1016\/j.ejca.2020.10.014_bib82","doi-asserted-by":"crossref","first-page":"134ra62","DOI":"10.1126\/scitranslmed.3003330","article-title":"CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients","volume":"4","author":"Rech","year":"2012","journal-title":"Sci Transl Med"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib83","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/mt.2011.269","article-title":"Phase I trial of \u201cbi-shRNAi(furin)\/GMCSF DNA\/autologous tumor cell\u201d vaccine (FANG) in advanced cancer","volume":"20","author":"Senzer","year":"2012","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.ejca.2020.10.014_bib84","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.2217\/imt.13.126","article-title":"Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1","volume":"5","author":"Vassilaros","year":"2013","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.ejca.2020.10.014_bib85","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jcyt.2013.11.013","article-title":"Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care","volume":"16","author":"Bapsy","year":"2014","journal-title":"Cytotherapy"},{"issue":"10","key":"10.1016\/j.ejca.2020.10.014_bib86","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1158\/2326-6066.CIR-14-0058","article-title":"A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer","volume":"2","author":"Chen","year":"2014","journal-title":"Cancer Inmunol Res"},{"issue":"4","key":"10.1016\/j.ejca.2020.10.014_bib87","doi-asserted-by":"crossref","first-page":"R70","DOI":"10.1186\/bcr3685","article-title":"Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients","volume":"16","author":"Takashashi","year":"2014","journal-title":"Breast Cancer Res"},{"issue":"23","key":"10.1016\/j.ejca.2020.10.014_bib88","doi-asserted-by":"crossref","first-page":"5964","DOI":"10.1158\/1078-0432.CCR-14-0059","article-title":"Safety and preliminary evidence of biologic efficacy of a mammaglobin-a DNA vaccine in patients with stable metastatic breast cancer","volume":"20","author":"Tiriveedhi","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.ejca.2020.10.014_bib89","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1001\/jamaoncol.2015.2736","article-title":"Docetaxel alone or in combination with a therapeutic cancer vaccine (PANVAC) in patients with metastatic breast cancer: a randomized clinical trial","volume":"1","author":"Heery","year":"2015","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ejca.2020.10.014_bib90","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1111\/cas.12757","article-title":"Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele","volume":"106","author":"Sakamoto","year":"2015","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.ejca.2020.10.014_bib91","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.3892\/ijo.2016.3386","article-title":"Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I\/II clinical trial","volume":"48","author":"Antonilli","year":"2016","journal-title":"Int J Oncol"},{"issue":"2","key":"10.1016\/j.ejca.2020.10.014_bib92","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10549-016-3750-y","article-title":"A phase I\/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer","volume":"156","author":"Curigliano","year":"2016","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib93","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10549-017-4130-y","article-title":"Safety and immunogenicity of neoadjuvant treatment using WT1-immunotherapeutic in combination with standard therapy in patients with WT1-positive stage II\/III breast cancer: a randomized phase I study","volume":"162","author":"Higgins","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"10.1016\/j.ejca.2020.10.014_bib94","doi-asserted-by":"crossref","first-page":"3014","DOI":"10.1158\/1078-0432.CCR-17-2499","article-title":"Folate receptor alpha peptide vaccine generates immunity in breast and ovarian cancer patients","volume":"24","author":"Kalli","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib95","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s00262-018-2257-2","article-title":"Phase I\/II clinical trial of a Wilms\u2019 tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer","volume":"68","author":"Zhang","year":"2019","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib96","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12094-018-1932-2","article-title":"Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers","volume":"21","author":"Chung","year":"2019","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib97","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-001-0255-1","article-title":"Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial","volume":"51","author":"Hernando","year":"2002","journal-title":"Cancer Immunol Immunother"},{"issue":"14","key":"10.1016\/j.ejca.2020.10.014_bib98","first-page":"5228","article-title":"Pilot study of Flt3 ligand comparing intraperitoneal with subcutaneous routes on hematologic and immunologic responses in patients with peritoneal carcinomatosis and mesotheliomas","volume":"9","author":"Fredman","year":"2003","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib99","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00002371-200401000-00006","article-title":"Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers","volume":"27","author":"Tsuda","year":"2004","journal-title":"J Immunother"},{"issue":"4","key":"10.1016\/j.ejca.2020.10.014_bib100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/CJI.0b013e31816dad10","article-title":"A multipeptide vaccine is safe and elicits T-cell responses in participants with advanced stage ovarian cancer","volume":"31","author":"Chianese-Bullock","year":"2008","journal-title":"J Immunother"},{"issue":"9","key":"10.1016\/j.ejca.2020.10.014_bib101","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1158\/1078-0432.CCR-07-4619","article-title":"Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission","volume":"14","author":"Diefenbach","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib102","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-09-2762","article-title":"Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer","volume":"70","author":"Galanis","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib103","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1158\/1078-0432.CCR-11-2121","article-title":"A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction","volume":"18","author":"Le","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib104","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/ijc.25980","article-title":"Long-term clinical and immunological effects of p53-SLP\u00ae vaccine in patients with ovarian cancer","volume":"130","author":"Leffers","year":"2012","journal-title":"Int J Cancer"},{"issue":"15","key":"10.1016\/j.ejca.2020.10.014_bib105","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1073\/pnas.1117208109","article-title":"Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients","volume":"109","author":"Odunsi","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib106","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s00262-011-1100-9","article-title":"A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients","volume":"61","author":"Rahma","year":"2012","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib107","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/mt.2011.269","article-title":"Phase I trial of \u201cbi-shRNAi(furin)\/GMCSF DNA\/autologous tumor cell\u201d vaccine (FANG) in advanced cancer","volume":"20","author":"Senzer","year":"2012","journal-title":"Mol Ther"},{"issue":"17","key":"10.1016\/j.ejca.2020.10.014_bib108","doi-asserted-by":"crossref","first-page":"4801","DOI":"10.1158\/1078-0432.CCR-13-1185","article-title":"A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside","volume":"19","author":"Chiang","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib109","doi-asserted-by":"crossref","first-page":"e2264","DOI":"10.4161\/onci.22664","article-title":"Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer","volume":"2","author":"Kandalaft","year":"2013","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib110","doi-asserted-by":"crossref","first-page":"224","DOI":"10.3109\/08923973.2014.913617","article-title":"Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients","volume":"36","author":"Kawano","year":"2014","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"10.1016\/j.ejca.2020.10.014_bib111","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/1757-2215-7-48","article-title":"The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer","volume":"7","author":"Kobayashi","year":"2014","journal-title":"J Ovarian Res"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib112","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1158\/2326-6066.CIR-13-0126","article-title":"Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian cancer","volume":"2","author":"Odunsi","year":"2014","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.ejca.2020.10.014_bib113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/cmi.2014.40","article-title":"Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I\/II trial","volume":"12","author":"Baek","year":"2015","journal-title":"Cell Mol Immunol"},{"issue":"31","key":"10.1016\/j.ejca.2020.10.014_bib114","doi-asserted-by":"crossref","first-page":"32228","DOI":"10.18632\/oncotarget.4772","article-title":"A phase 1\/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer","volume":"6","author":"Dijkgraaf","year":"2015","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.ejca.2020.10.014_bib115","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1158\/1078-0432.CCR-17-2709","article-title":"p53-Reactive T cells are associated with clinical benefit in patients with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and gemcitabine chemotherapy","volume":"24","author":"Hardwick","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.ejca.2020.10.014_bib116","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2019.09.015","volume":"155","author":"O\u2019Cearbhaill","year":"2019","journal-title":"Gynecol Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920312739?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804920312739?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:29:44Z","timestamp":1760732984000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804920312739"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":116,"alternative-id":["S0959804920312739"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of cancer vaccines in selected gynaecological breast and ovarian\u00a0cancers: A 20-year systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2020.10.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}